Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSMIC-312: cabozantinib + atezolizumab versus sorafenib, with exploratory cabozantinib monotherapy, in previously untreated advanced hepatocellular carcinoma
MOH_2019-02-14_005961Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing cabozantinib + atezolizumab, Control: sorafenib and Exploratory: cabozantinib (3 arms). Started Jan 2019; status: completed.
02
Drugs
cabozantinibatezolizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2019-02-14_005961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-14_005961.